I am a breastfeeding mother and i want to know if it is safe to use Afeditab CR? Is Afeditab CR safe for nursing mother and child? Does Afeditab CR extracts into breast milk? Does Afeditab CR has any long term or short term side effects on infants? Can Afeditab CR influence milk supply or can Afeditab CR decrease milk supply in lactating mothers?
- DrLact safety Score for Afeditab CR is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of Afeditab CR is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that Afeditab CR does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of Afeditab CR safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Excreted into breast milk in non-significant amount with no problems among breastfed infants whose mothers were treated with this medication. No alteration on breast milk composition has been seen. Shown to be effective at a dose of 10 - 20 mg three times-a-day for pain relief related to Raynaud's phenomena of the nipple, which is a highly painful vasospasm triggered by cold exposition or trauma produced by inadequate latch-on to the breast. Side effect on the mother should be addressed. American Academy of Pediatrics 2001: Maternal Medication Usually Compatible With Breastfeeding. Eleventh WHO Model List of Essential Drugs 2002: Compatible with breastfeeding.
Because of the low levels of Afeditab CR in breastmilk, amounts ingested by the infant are small and no adverse effects have been reported among a limited number of infants exposed to Afeditab CR in breastmilk. Afeditab CR is used to treat painful nipple vasospasm (e.g., Raynaud phenomenon) in nursing mothers.[1]
No adverse reactions have been reported among infants exposed to Afeditab CR in breastmilk mostly at maternal dosages of 30 mg daily beginning shortly postpartum and continuing for up to 6 months in some.[2][5][6][7][8][9][10][11]
No direct effects are known. However, Afeditab CR has been used to decrease the pain of nipple vasospasm (or Raynaud phenomenon of the nipple), allowing mothers to continue nursing who might otherwise discontinue breastfeeding. The dosage of Afeditab CR reportedly used to treat the condition is 30 to 60 mg daily either as a single dose of a sustained-release product or 10 to 20 mg 3 times daily of an immediate-release product. Lower dosages can be tried if these doses are not tolerated.[1][6][7][8][9][12] Afeditab CR had no effect on milk composition (sodium, potassium, calcium, chloride, nitrogen, phosphorus and total lipids) in one woman.[3]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.